AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:FBIOFortress Biotech Stock Price, Forecast & News

$2.69
0.00 (0.00 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.58
Now: $2.69
$2.72
50-Day Range
$2.54
MA: $2.82
$3.16
52-Week Range
$1.04
Now: $2.69
$3.20
Volume550,600 shs
Average Volume639,762 shs
Market Capitalization$221.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Read More
Fortress Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.63 million
Book Value$1.02 per share

Profitability

Net Income$-39,960,000.00
Net Margins-124.73%

Miscellaneous

Employees93
Market Cap$221.86 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

How has Fortress Biotech's stock been impacted by COVID-19 (Coronavirus)?

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FBIO shares have increased by 67.1% and is now trading at $2.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fortress Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fortress Biotech.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fortress Biotech.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The biopharmaceutical company had revenue of $12.92 million for the quarter, compared to analysts' expectations of $11.44 million. Fortress Biotech had a negative return on equity of 58.31% and a negative net margin of 124.73%. View Fortress Biotech's earnings history.

What price target have analysts set for FBIO?

4 brokers have issued twelve-month target prices for Fortress Biotech's shares. Their forecasts range from $6.00 to $19.00. On average, they anticipate Fortress Biotech's stock price to reach $10.50 in the next year. This suggests a possible upside of 290.3% from the stock's current price. View analysts' price targets for Fortress Biotech.

Has Fortress Biotech been receiving favorable news coverage?

Headlines about FBIO stock have trended negative on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fortress Biotech earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Fortress Biotech.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 539,000 shares, an increase of 17.3% from the June 15th total of 459,600 shares. Based on an average trading volume of 640,500 shares, the short-interest ratio is currently 0.8 days. Approximately 0.9% of the shares of the company are short sold. View Fortress Biotech's Current Options Chain.

Who are some of Fortress Biotech's key competitors?

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Advanced Micro Devices (AMD), TG Therapeutics (TGTX), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Amarin (AMRN), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Dynavax Technologies (DVAX) and Geron (GERN).

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 65, Pay $532.57k)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 58, Pay $1.8M)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 66, Pay $386.35k)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. & Director (Age 54, Pay $532.57k)
  • Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $2.69.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $221.86 million and generates $36.63 million in revenue each year. The biopharmaceutical company earns $-39,960,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Fortress Biotech employs 93 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is www.fortressbiotech.com.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]tech.com.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.